Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-1 15% subcutaneous versus Liquid Alpha1-PI intravenous PK and safety study in alpha-1 antitrypsin deficiency
NL-OMON60660Phase 3Recruiting
- Sponsor
- Grifols
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of alpha1-proteinase inhibitor subcutaneous (human) 15% and alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Grifols. Started Jun 2026; status: recruiting.
02
Drugs
alpha1-proteinase inhibitor subcutaneous (human) 15%alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NL-OMON60660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60660.